vbid/9780443224218

Description

CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR �Cas systems for metabolic disorders, Recent progress in CRISPR �Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR �Cas systems for cataract and blindness, Advances in CRISPR �Cas systems for muscular dystrophy, Recent development in CRISPR �Cas systems for cardiac disease, Current approaches in CRISPR �Cas systems for diabetes, and much more.

Additional sections cover Advances in CRISPR �Cas systems for liver disease, Advances in CRISPR �Cas systems for lung disease, Advances in CRISPR �Cas systems for kidney diseases, Current progress in CRISPR �Cas systems for rare disease, Advances in CRISPR �Cas systems for heredity disease, Recent progress in CRISPR �Cas systems for neurological disorders, and CRISPR challenges in clinical developments.

• Provides CRISPR-Cas systems for metabolic disorders, retinal disease cataracts, and blindness
• Offer updates on muscular dystrophy, cardiac disease, diabetes, and liver disease
• Includes content on lung disease, kidney diseases, rare diseases, heredity diseases, neurological disorders, and CRISPR challenges in clinical developments

Typham this is the title: CRISPR-Cas-Based Genome Editing for Treating Human Diseases – Part B